204 related articles for article (PubMed ID: 23007010)
1. Endpoints for clinical trials and revised assessment in neuro-oncology.
Butowski N; Chang SM
Curr Opin Neurol; 2012 Dec; 25(6):780-5. PubMed ID: 23007010
[TBL] [Abstract][Full Text] [Related]
2. Endpoints in cancer clinical trials.
Fiteni F; Westeel V; Pivot X; Borg C; Vernerey D; Bonnetain F
J Visc Surg; 2014 Feb; 151(1):17-22. PubMed ID: 24440056
[TBL] [Abstract][Full Text] [Related]
3. Clinical trial end points for high-grade glioma: the evolving landscape.
Reardon DA; Galanis E; DeGroot JF; Cloughesy TF; Wefel JS; Lamborn KR; Lassman AB; Gilbert MR; Sampson JH; Wick W; Chamberlain MC; Macdonald DR; Mehta MP; Vogelbaum MA; Chang SM; Van den Bent MJ; Wen PY
Neuro Oncol; 2011 Mar; 13(3):353-61. PubMed ID: 21310734
[TBL] [Abstract][Full Text] [Related]
4. [Health related quality of life and endpoints in oncology].
Bonnetain F
Cancer Radiother; 2010 Oct; 14(6-7):515-8. PubMed ID: 20674446
[TBL] [Abstract][Full Text] [Related]
5. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas.
van den Bent MJ; Wefel JS; Schiff D; Taphoorn MJ; Jaeckle K; Junck L; Armstrong T; Choucair A; Waldman AD; Gorlia T; Chamberlain M; Baumert BG; Vogelbaum MA; Macdonald DR; Reardon DA; Wen PY; Chang SM; Jacobs AH
Lancet Oncol; 2011 Jun; 12(6):583-93. PubMed ID: 21474379
[TBL] [Abstract][Full Text] [Related]
6. Issues in assessing and interpreting quality of life in patients with malignant glioma.
Gilbert M; Armstrong T; Meyers C
Semin Oncol; 2000 Jun; 27(3 Suppl 6):20-6. PubMed ID: 10866346
[TBL] [Abstract][Full Text] [Related]
7. Clinical trial end points in malignant glioma: need for effective trial design strategy.
Brada M; Yung WK
Semin Oncol; 2000 Jun; 27(3 Suppl 6):11-9. PubMed ID: 10866345
[TBL] [Abstract][Full Text] [Related]
8. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
9. Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?
Amir E; Seruga B; Kwong R; Tannock IF; Ocaña A
Eur J Cancer; 2012 Feb; 48(3):385-8. PubMed ID: 22115991
[TBL] [Abstract][Full Text] [Related]
10. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
Wen PY; Macdonald DR; Reardon DA; Cloughesy TF; Sorensen AG; Galanis E; Degroot J; Wick W; Gilbert MR; Lassman AB; Tsien C; Mikkelsen T; Wong ET; Chamberlain MC; Stupp R; Lamborn KR; Vogelbaum MA; van den Bent MJ; Chang SM
J Clin Oncol; 2010 Apr; 28(11):1963-72. PubMed ID: 20231676
[TBL] [Abstract][Full Text] [Related]
11. Pros and cons of current brain tumor imaging.
Ellingson BM; Wen PY; van den Bent MJ; Cloughesy TF
Neuro Oncol; 2014 Oct; 16 Suppl 7(Suppl 7):vii2-11. PubMed ID: 25313235
[TBL] [Abstract][Full Text] [Related]
12. Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials.
Bellera CA; Pulido M; Gourgou S; Collette L; Doussau A; Kramar A; Dabakuyo TS; Ouali M; Auperin A; Filleron T; Fortpied C; Le Tourneau C; Paoletti X; Mauer M; Mathoulin-Pélissier S; Bonnetain F
Eur J Cancer; 2013 Mar; 49(4):769-81. PubMed ID: 23122780
[TBL] [Abstract][Full Text] [Related]
13. Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels.
Willke RJ; Burke LB; Erickson P
Control Clin Trials; 2004 Dec; 25(6):535-52. PubMed ID: 15588741
[TBL] [Abstract][Full Text] [Related]
14. Outcomes and endpoints in trials of cancer treatment: the past, present, and future.
Wilson MK; Karakasis K; Oza AM
Lancet Oncol; 2015 Jan; 16(1):e32-42. PubMed ID: 25638553
[TBL] [Abstract][Full Text] [Related]
15. Interpreting clinical trials in lung cancer: impact of methodology and endpoints.
Gralla RJ; Griesinger F
J Thorac Oncol; 2007 Jun; 2 Suppl 2():S51-8. PubMed ID: 17589300
[TBL] [Abstract][Full Text] [Related]
16. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma.
Tsao MN; Mehta MP; Whelan TJ; Morris DE; Hayman JA; Flickinger JC; Mills M; Rogers CL; Souhami L
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):47-55. PubMed ID: 16111571
[TBL] [Abstract][Full Text] [Related]
17. Pseudoprogression and pseudoresponse in the treatment of gliomas.
Brandsma D; van den Bent MJ
Curr Opin Neurol; 2009 Dec; 22(6):633-8. PubMed ID: 19770760
[TBL] [Abstract][Full Text] [Related]
18. Evaluating health-related quality of life and symptom burden in brain tumour patients: instruments for use in experimental trials and clinical practice.
Mauer ME; Bottomley A; Taphoorn MJ
Curr Opin Neurol; 2008 Dec; 21(6):745-53. PubMed ID: 18989121
[TBL] [Abstract][Full Text] [Related]
19. A comparison of treatment results for recurrent malignant gliomas.
Nieder C; Grosu AL; Molls M
Cancer Treat Rev; 2000 Dec; 26(6):397-409. PubMed ID: 11139371
[TBL] [Abstract][Full Text] [Related]
20. Placebo effect-adjusted assessment of quality of life in placebo-controlled clinical trials.
Eickhoff JC
Stat Med; 2008 Apr; 27(9):1387-402. PubMed ID: 18219702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
